Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tendonitis Treatment Market

Tendonitis Treatment Market Trends

Report ID: GMI8326
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Tendonitis Treatment Market Trends

Market expansion is anticipated to be propelled by the introduction of innovative tendonitis treatment techniques. Recently introduced advanced imaging technologies such as ultrasound and MRI, specialized surgical instruments has improved the diagnosis and monitoring of tendonitis. Shockwave therapy, 3D printing for orthopedic implants, robot-assisted surgery, functional electrical stimulation, and all these contribute to more precise diagnostics, individualized treatment plans, and improved patient outcomes in the management of tendonitis, thereby promoting demand for tendonitis treatment.

The shift from static to dynamic variable monitoring and the advancement of minimally invasive monitoring approaches are projected to foster market growth in the forecast period.
For instance, in September 2021, Stryker's Trauma and Extremities division successfully launched the Citrelock Tendon Trauma Fixation Device System. This innovative system presented surgeons with a distinctive design, incorporating a tendon thread utilizing the proprietary resorbable technology and benefited company by expanding its product portfolio in the orthopedic surgery domain.
Furthermore, the escalating preference for tendon repair market has also stimulated increased focus on research and development, aiming to improve the overall experience for patients, enhance treatment outcomes, and advance the efficiency of tendonitis therapy.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Tendonitis treatment industry reached a revenue of USD 214.6 billion in 2023 and is estimated to cross USD 297.9 billion by 2032 attributed to the rising prevalence of sedentary, lifestyles, continual growth of healthcare expenditure, and the ongoing technological advancements.

The achilles tendonitis application segment is expected to generate USD 142.7 billion in revenue by the end of 2032 as it offers significant advantages to patients with effective relief without the need for surgery or invasive procedures.

North America tendonitis treatment industry size was USD 87 billion in 2023 and is set to expand at a notable CAGR through 2032 owing to the presence of sophisticated healthcare infrastructure, and an increased prevalence of tendonitis cases in the region.

Some of the major tendonitis treatment firms are Abbott Laboratories, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb Company, Colfax Corporation, GalxoSmithKline AG, Johnson & Johnson, Merck and Co., Inc., Ossur, Pifzer Inc., Stryker Corporation, Teva Pharmaceutical Industries Ltd., Tynor Orthotics Pvt. Ltd, and Zimmer Biomet Holdings, Inc.